King Rachel K.
- SEC CIK
- 0001589712
No open-market purchases or sales filed in the past year.
Current role at each company
- FULC Fulcrum Therapeutics, Inc.Directoras of Jul 2, 2026
- NVAX Novavax IncDirectoras of Jun 23, 2026
- CBIO Crescent Biopharma, Inc.Directoras of May 1, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists King Rachel K. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
NVAX Novavax Inc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 (view filing) | Dec 13, 2024 | 20 daysLate | King Rachel K.Director | SSale | −4.15K | $9.02 | −$37.4K | −21.9%14.8K after |